20 March 2025

The Manesq laboratory is merging with the CerbaHealthCare group

Cession

sector Health

The Manesq medical biology laboratory network chooses to join Cerba Healthcare.

Customer Selarl Manesq

Manesq is an independent medical biology player based in the Alpes-de-Haute-Provence region. With 3 collection sites and a technical platform in Manosque, the laboratory generates a revenue of €6.5 million.

Counterparties Cerba Healthcare

Cerba Healthcare is one of the global leaders in medical biology. Bringing together nearly 600 biologists within its 450 local laboratories and 150 collection centers, the group operates across five complementary activities: specialized medical biology, local medical biology, veterinary biology and genetics, clinical trials biology, and diagnostic clinical trials biology.

Led by Jérôme Peretti, Manesq is an independent player in medical biology located in the Alpes-de-Haute-Provence. With 3 sampling sites and a technical platform in Manosque, the laboratory generates a turnover of €6.5 million.

Seeking to partner with a national player, the three associate biologists mandated Pax Corporate Finance to assist them in this process. After discussions with the main French players, Cerba Healthcare stood out from the competition by proposing a project in which Manesq would be at the heart of the development of its new Cerballiance Hautes-Alpes Durance division.

Cerba Healthcare is a global leader in medical biology. With nearly 600 biologists across 450 local laboratories and 150 sampling centers, the group operates in five complementary areas:

Specialized medical biology centered around the Cerba Laboratory
Local medical biology
Veterinary biology and genetics
Clinical trial biology
Diagnostic trial biology

With a presence on five continents, Cerba Healthcare cares for over 25 million patients annually. This acquisition allows the group to expand its national coverage by developing the new Cerballiance Hautes-Alpes Durance division based on an already well-established laboratory.

Thus, the Manesq laboratory continues its local development while benefiting from important synergies, particularly in bacteriology.

"Given the new challenges in medical biology, both medically and financially, the shareholders of Manesq decided to join forces with a major national group. In this context, we chose to be assisted by Pax Corporate Finance, a specialist in such merger operations within our sector, to optimize the price and conditions of this transaction. This merger will ensure the sustainability of the existing technical platform in the Manosque area, with a superior technical offering," says Jérôme Peretti.